HUP0301954A2 - Orto-szubsztituált antranilsav-amidok és felhasználásuk gyógyszerként - Google Patents

Orto-szubsztituált antranilsav-amidok és felhasználásuk gyógyszerként

Info

Publication number
HUP0301954A2
HUP0301954A2 HU0301954A HUP0301954A HUP0301954A2 HU P0301954 A2 HUP0301954 A2 HU P0301954A2 HU 0301954 A HU0301954 A HU 0301954A HU P0301954 A HUP0301954 A HU P0301954A HU P0301954 A2 HUP0301954 A2 HU P0301954A2
Authority
HU
Hungary
Prior art keywords
ortho
acid amides
anthranilic acid
medicaments
substituted anthranilic
Prior art date
Application number
HU0301954A
Other languages
English (en)
Inventor
Alexander Ernst
Martin Haberey
Anrreas Huth
Martin Krüger
Andreas Menrad
Orlin Petrov
Dieter Seidelmann
Karl-Heinz Thierauch
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of HUP0301954A2 publication Critical patent/HUP0301954A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány (I) általános képletű orto-szubsztituált antranilsav-amidokra és gyógyszerként történő felhasználásukra vonatkozik olyanbetegségek kezeléséhez, amelyek pertiszten: angingenezis soránalakulnak ki. Az (I) általános képletben R1 jelentése az alábbiképletű csoportok egyike, ahol R5 jelentése klóratom, brómatom vagy -OCH3 csoport, ahol R7jelentése metilcsoport vagy klóratom, R2 jelentése piridil- vagy azalábbi csoportok egyike, és R3 jelentése hidrogén- vagy fluoratom,valamint ezek izomerjei és sói. Ó
HU0301954A 2000-05-09 2001-05-08 Orto-szubsztituált antranilsav-amidok és felhasználásuk gyógyszerként HUP0301954A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10023486A DE10023486C1 (de) 2000-05-09 2000-05-09 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
PCT/EP2001/005214 WO2001085719A1 (de) 2000-05-09 2001-05-08 Ortho substituierte anthranilsäureamide und deren verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
HUP0301954A2 true HUP0301954A2 (hu) 2003-09-29

Family

ID=7641923

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301954A HUP0301954A2 (hu) 2000-05-09 2001-05-08 Orto-szubsztituált antranilsav-amidok és felhasználásuk gyógyszerként

Country Status (31)

Country Link
US (2) US7081468B2 (hu)
EP (1) EP1280799B1 (hu)
JP (1) JP2003532725A (hu)
KR (1) KR20020094024A (hu)
CN (1) CN1237062C (hu)
AT (1) ATE258174T1 (hu)
AU (2) AU7400101A (hu)
BG (1) BG107261A (hu)
BR (1) BR0110621A (hu)
CA (1) CA2407852A1 (hu)
CZ (1) CZ20023677A3 (hu)
DE (2) DE10023486C1 (hu)
DK (1) DK1280799T3 (hu)
EE (1) EE04938B1 (hu)
ES (1) ES2214424T3 (hu)
HK (1) HK1056728A1 (hu)
HR (1) HRP20020977B1 (hu)
HU (1) HUP0301954A2 (hu)
IL (2) IL152578A0 (hu)
MX (1) MXPA02010915A (hu)
NO (1) NO323541B1 (hu)
NZ (1) NZ521700A (hu)
PL (1) PL358204A1 (hu)
PT (1) PT1280799E (hu)
RU (1) RU2264399C2 (hu)
SK (1) SK15882002A3 (hu)
TR (1) TR200400912T4 (hu)
UA (1) UA73187C2 (hu)
WO (1) WO2001085719A1 (hu)
YU (1) YU82702A (hu)
ZA (1) ZA200209896B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
CN1671666A (zh) * 2002-07-31 2005-09-21 舍林股份公司 Vegfr－2和vegfr－3抑制性的邻氨基苯甲酰胺吡啶化合物
EP1628661A2 (en) * 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
DE10327719A1 (de) * 2003-06-13 2005-01-20 Schering Ag VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
US7202260B2 (en) * 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
EP1668013B1 (en) 2003-09-23 2012-02-22 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
DE102004011720B4 (de) * 2004-03-10 2008-04-03 Bayer Schering Pharma Aktiengesellschaft Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie
US7427390B2 (en) * 2004-03-10 2008-09-23 Schering Ag Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
JP5169220B2 (ja) * 2005-11-30 2013-03-27 アステラス製薬株式会社 ２−アミノベンズアミド誘導体
KR102392684B1 (ko) 2014-01-13 2022-04-29 오리진 디스커버리 테크놀로지스 리미티드 Irak4 억제제로서의 바이시클릭 헤테로시클릴 유도체
KR20170016500A (ko) * 2014-06-20 2017-02-13 오리진 디스커버리 테크놀로지스 리미티드 Irak4 저해제로서의 치환된 인다졸 화합물
IL293783B2 (en) 2017-03-31 2024-01-01 Aurigene Oncology Ltd Compounds and preparations for the treatment of hematological disorders
PL3704108T3 (pl) 2017-10-31 2024-07-22 Curis, Inc. Inhibitor irak4 w połączeniu z inhibitorem bcl-2 do stosowania w leczeniu nowotworu złośliwego

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409668A (en) * 1964-11-07 1968-11-05 Palazzo Giuseppe Substituted anthranilamides and process for the preparation thereof
FR2689508B1 (fr) * 1992-04-01 1994-06-17 Fournier Ind & Sante Derives de l'imidazole, leur procede de preparation et leur application en therapeutique.
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
DE10023492A1 (de) * 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
MXPA03010099A (es) * 2001-05-08 2004-03-10 Schering Ag Amidas de antranilamida-piridina selectivas como inhibidores de vegfr-2 y vegfr-3.
US20040039019A1 (en) * 2002-06-19 2004-02-26 Schering Ag Selected anthranilaminde pyridinamides and their use as pharmaceutical agents
US7517894B2 (en) * 2002-07-31 2009-04-14 Bayer Schering Pharma Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7615565B2 (en) * 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7202260B2 (en) * 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
MX2007000816A (es) * 2004-07-19 2007-06-05 Thia Medica As Composicion que comprende material de proteina y compuestos que comprenden entidades de acido graso no oxidable.
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) * 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) * 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US20060266770A1 (en) * 2005-05-26 2006-11-30 Fitzgerald Robert M Portable dispensers comprising a mobile dispenser and mobile storage cartridge

Also Published As

Publication number Publication date
NO20025358D0 (no) 2002-11-08
IL152578A (en) 2008-11-03
HK1056728A1 (en) 2004-02-27
HRP20020977A2 (en) 2005-02-28
KR20020094024A (ko) 2002-12-16
NO323541B1 (no) 2007-06-11
AU7400101A (en) 2001-11-20
DE10023486C1 (de) 2002-03-14
CN1427837A (zh) 2003-07-02
YU82702A (sh) 2006-05-25
BG107261A (bg) 2003-06-30
ZA200209896B (en) 2004-03-05
EP1280799B1 (de) 2004-01-21
NZ521700A (en) 2005-09-30
EP1280799A1 (de) 2003-02-05
EE04938B1 (et) 2007-12-17
SK15882002A3 (sk) 2003-08-05
RU2264399C2 (ru) 2005-11-20
MXPA02010915A (es) 2003-07-14
WO2001085719A9 (de) 2001-12-27
US20040102441A1 (en) 2004-05-27
JP2003532725A (ja) 2003-11-05
PL358204A1 (en) 2004-08-09
BR0110621A (pt) 2003-03-25
WO2001085719A1 (de) 2001-11-15
US20060014747A1 (en) 2006-01-19
DE50101364D1 (de) 2004-02-26
TR200400912T4 (tr) 2004-07-21
UA73187C2 (en) 2005-06-15
AU2001274001B2 (en) 2007-01-18
ES2214424T3 (es) 2004-09-16
CZ20023677A3 (cs) 2003-02-12
DK1280799T3 (da) 2004-05-10
US7081468B2 (en) 2006-07-25
IL152578A0 (en) 2003-05-29
NO20025358L (no) 2002-11-08
PT1280799E (pt) 2004-06-30
CN1237062C (zh) 2006-01-18
ATE258174T1 (de) 2004-02-15
HRP20020977B1 (en) 2008-05-31
CA2407852A1 (en) 2001-11-15
EE200200625A (et) 2004-04-15

Similar Documents

Publication Publication Date Title
HUP0301954A2 (hu) Orto-szubsztituált antranilsav-amidok és felhasználásuk gyógyszerként
NL300933I2 (nl) Letermovir
YU71102A (sh) Supstituisani amidi benzoeve kiseline i njihova primena kao sredstva za lečenje
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
NO20051726L (no) Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser
CY1110019T1 (el) Συνδυασμενη θεραπεια με υποκατεστημενες οξαζολιδινονες
ATE411288T1 (de) Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
NO20014484L (no) Nye forbindelser og sammensetninger som proteaseinhibitorer
TR200401962T4 (tr) Heteroaromatik karboksamid türevleri ve bunların IKK-2 enziminin inhibitörleri olarak kullanımı
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
CY1108085T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπ-2-εν-1-ονης παρασκευη και χρησης αυτων
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
CY1111543T1 (el) Νεες ενωσεις
IS2879B (is) a-(N-súlfonamíðó)asetamíðafleiður sem ß-amýlóíðtálmar
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
CY1105441T1 (el) Ετepοκυκλικοι σουλφοναμιδικοι αναστολεις της παραγωγης βητα αμυλοειδους
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
UY26851A1 (es) Derivados de la 4-fenilpiridina
NO20063308L (no) Kombinasjon av flupirtin og tramadol
EA200001061A1 (ru) Фармацевтическая композиция
ATE344262T1 (de) 2-heteroarylcarbonsäureamide
NO20060733L (no) Pyrazoliner som PAR-1 antagonister for behandling av kardiovaskulaere sykdommer
TW200612940A (en) Substituted tetrahydroisoquinolines as mmp inhibitors, process for their preparation and their use as medicament

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished